Meredith Delk
About Meredith Delk
Meredith Delk, Ph.D., is InnovAge’s Chief Administrative Officer, appointed in October 2025 after serving as a consultant to the company via her firm, Delk Strategies, from April–October 2025 . She is 53 years old and is listed among the company’s executive officers in the 2025 proxy . Her background includes senior leadership roles in state government health solutions and government affairs across Prime Therapeutics (formerly Magellan Rx), Magellan Health, Anthem (Elevance), and Amerigroup; she holds a Master’s in Social Work (University of Central Florida) and a Ph.D. (University of Florida) . Companywide performance metrics (TSR, revenue growth, EBITDA growth) tied specifically to her tenure are not disclosed in public filings to date; InnovAge remains a smaller reporting/emerging growth company and provides scaled executive compensation disclosure .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Prime Therapeutics (previously Magellan Rx) | Senior Vice President and General Manager, State Government Solutions Division | 2018–2024 | Led the state government solutions division, overseeing strategy and operations serving government programs . |
| Magellan Health | Led Government Affairs teams | 2015–2021 | Directed government affairs across regulated healthcare markets, supporting payer/provider engagement . |
| Anthem (now Elevance Health) | Government Affairs leadership | 2013–2014 | Advanced government relations for a major national health benefits provider . |
| Amerigroup Corporation | Government Affairs leadership | 2009–2013 | Drove government-focused initiatives within a Medicaid/Medicare-centered enterprise . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Delk Strategies | Founder/Principal (consultant to InnovAge) | Apr–Oct 2025 | Provided advisory services to InnovAge prior to joining as Chief Administrative Officer . |
Fixed Compensation
- Not disclosed for Dr. Delk in InnovAge’s FY2025 or FY2024 proxy statements; she is not included among the Named Executive Officers covered by the Summary Compensation Table for those periods .
Performance Compensation
- Not disclosed for Dr. Delk. FY2025 annual bonus mechanics and payouts were disclosed for the CEO, President/COO, and CLO (target performance achieved), but Dr. Delk was not a Named Executive Officer in those disclosures .
Equity Ownership & Alignment
- Hedging and pledging prohibited: InnovAge’s Insider Trading Policy bans hedging/monetization strategies (e.g., collars, swaps) and prohibits holding/pledging company securities in margin accounts or as loan collateral, which reduces misalignment risk from hedging or pledging by executive officers .
- Beneficial ownership for Dr. Delk is not disclosed in available beneficial ownership tables; her appointment postdates prior ownership tables and she is not listed therein .
- Stock ownership guidelines and compliance status: No executive-specific ownership guidelines or Dr. Delk’s compliance disclosures are provided in the available proxies .
Employment Terms
- Role and start date: Chief Administrative Officer since October 2025; consultant to InnovAge via Delk Strategies from April–October 2025 .
- Executive officer status: Listed among current executive officers (age 53) in the 2025 proxy .
- Clawback policy: Company adopted a clawback policy effective September 7, 2023, compliant with Nasdaq Rule 5608 and Section 10D of the Exchange Act; it requires reimbursement/forfeiture of excess incentive-based compensation for the three preceding fiscal years in the event of a restatement .
- Change-in-control and severance: Company-level severance and vesting provisions are disclosed for Named Executive Officers (CEO, President/COO, CLO) regarding salary+bonus multiples, healthcare coverage continuation, and award acceleration/assumption mechanics; no agreement terms are disclosed for Dr. Delk specifically .
- Non-compete/solicit: Company employment agreements outline non-compete/non-solicit periods for certain Named Executive Officers; no executive-specific restrictive covenant disclosure is provided for Dr. Delk .
Investment Implications
- Newly appointed senior operator with deep Medicaid/Medicare/government-affairs credentials: Dr. Delk’s background spans government solutions and payer relations—capabilities central to InnovAge’s regulatory and compliance-intensive PACE model, potentially supporting execution on growth/restoration initiatives .
- Alignment safeguards: Company prohibitions on hedging/pledging and a formal clawback policy mitigate misalignment and recoup risk for incentive-based pay, though executive-specific equity ownership and award structures for Dr. Delk are not yet disclosed .
- Disclosure constraints and retention visibility: As an emerging growth/smaller reporting company, InnovAge provides scaled executive compensation disclosure, and Dr. Delk is not a Named Executive Officer in FY2025 filings—limiting visibility into her base pay, bonus targets, severance, and LTI design; monitoring future proxies and any Form 8-K appointments or Form 4 filings remains critical for assessing insider selling pressure and retention economics .
- Team transition context: The announced departure of the President/COO in late 2025 highlights ongoing leadership transitions, increasing the importance of administrative and regulatory execution—areas aligned to Dr. Delk’s expertise .